Asia-Pacific Heparin Market, By Product Type (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)), Mode of Administration (Oral, Parenteral), Source (Bovine, Porcine), Ingredients (Sodium, Calcium, Others), Availability (Raw, Processed), Treatment (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism, Others), Application (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests, Others), Therapeutics (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Strength (10 Unit, 100 Unit, 1000 Unit, 5000 Unit, 10000 Unit, 25000 Unit, Others), Type (Generics, Brands), Container (Bottles, Bags, Vials, Others), Packaging (Glass, Plastic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Asia-Pacific Heparin Market Analysis and Size
The increase in venous thromboembolism and cardiovascular diseases is the primary factor enhancing the market growth rate. Several medical device manufacturers and suppliers are shifting their focus to emerging and supplying COVID-19 essentials and medical devices for respiratory diseases that affect the operations of the numerous market players in this region. Additionally, increasing health care expenditure and initiatives undertaken by government bodies are some of the major factors estimated to drive the market growth.
Data Bridge Market Research analyses a growth rate in the heparin market in the forecast period 2023-2030. The expected CAGR of heparin market is tend to be around 5.50% in the mentioned forecast period. The market is valued at USD 1.3 billion in 2022, and it would grow upto USD 2 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Heparin Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)), Mode of Administration (Oral, Parenteral), Source (Bovine, Porcine), Ingredients (Sodium, Calcium, Others), Availability (Raw, Processed), Treatment (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism, Others), Application (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests, Others), Therapeutics (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Strength (10 Unit, 100 Unit, 1000 Unit, 5000 Unit, 10000 Unit, 25000 Unit, Others), Type (Generics, Brands), Container (Bottles, Bags, Vials, Others), Packaging (Glass, Plastic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Sanofi (France), Pfizer Inc (U.S.), Merck & Co., Inc. (U.S.), Abbott (U.S.), Mylan N.V. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Aspen Holdings (U.S.), Changzhaou Qianhong Bio-pharma Co., ltd. (China), Fresenius Kabi AG (Germany), Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China), Hikma Pharmaceuticals PLC (U.K.), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), OPOCRIN SPA (Italy), SARIA International GmbH (Germany), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Yino Pharma Limited, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China), Hepalink Group. (China)
|
|
Market Opportunities
|
|
Market Definition
Heparin is a type of drug that prevents and treats blood clots. It is used to treat blood coagulation abnormalities. It is also used to prevent blood clotting after surgery, during dialysis, blood transfusions, and when taking blood samples. It is all treated with the disseminated intravascular coagulation, pulmonary embolism, deep vein thrombosis, and arterial thromboembolism. It does not eliminate blood clots; instead, it prevents them from increasing larger and creating more catastrophic complications.
Asia-Pacific Heparin Market Dynamics
Drivers
- Increasing Prevalence of Venous Thromboembolism
The occurrence of thromboembolism differs considerably between different ethnic and population groups in Asia-Pacific region. In Japan, the occurrence of VTE is reportedly about one-eighth of North Americans. Furthermore, the other possible hereditary risk factors are hyperhomocysteinemia and increased levels of Factors I, VIII, and XI. Though, the differences are because of the lack of well-designed studies and non-standardized survey designs. The occurrence of VTE in Asian countries has doubled in the past decade. This could be attributed to lifestyle changes, the aging population, and growing awareness of VTE. Thromboembolism in COVID-19 patients are a major concern for clinicians. A Chinese study this is conducted on COVID-19 ICU patients stated 46–85.4% DVT incidence. China is expecting a remarkable recovery for NMH, with the resumption of trade operations after the relaxation of lockdown. Thus, this factor increases the market growth.
Opportunities
- Increase in Coronary Artery Disease
The coronary artery disease increases the market growth due to the increasing occurrence of heart-related disorders. The lack of physical activity, high blood pressure, and excess smoking are major factors leading to the increased incidence of coronary artery disease. The growing number of hospital stay days post-surgery and bedridden patients with limited movements creates a major opportunity for heparin since they are at heavy risk of blood clot development. This as a result, increases the demand for the market.
- Rising Incidence of Subcutaneous Administration
The subcutaneous segment dominated the market share and accounted for the largest revenue share of 64.8% in 2021 due to low hospitalization-associated costs, increasing demand for home care treatment, and the increasing advantages such as ease in administration are estimated to boost the market growth. The advanced compliance rate of patients for subcutaneous heparin acts as a major advantage for the segment. Thus, this boosts the market growth.
Restraints/Challenges
- High Cost of Treatment
The growing expenditure related to the drugs, the varied tests, and the cost required to conduct the assays hamper market growth. There are numerous drugs that cost high and people in the highly developing and underdeveloped countries, cause the under treatment of numerous patients. This impedes the market growth.
This heparin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the heparin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Asia-Pacific Heparin Market Scope
The heparin market is segmented on the basis of product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWH)
- Ultra-Low Molecular Weight Heparin (ULMWH)
Mode of Adminstration
- Oral
- Parenteral
Source
- Bovine
- Porcine
Ingredients
- Sodium
- Calcium
- Others
Availability
- Raw
- Processed
Treatment
- Deep Vein Thrombosis
- Pulmonary Embolism
- Arterial Thromboembolism
- Others
Application
- Pre-Surgical Procedures
- Post-Surgical Procedures
- Kidney Dialysis
- Diagnostic Tests
- Others
Therapeutics
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
Strength
- 10 Unit
- 100 Unit
- 1000 Unit
- 5000 Unit
- 10000 Unit
- 25000 Unit
- Others
Type
- Generics
- Brands
Container
- Bottles
- Bags
- Vials
- Others
Packaging
- Glass
- Plastic
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Heparin Market Regional Analysis/Insights
The heparin market is analyzed and market size insights and trends are provided by product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-users and distribution channel as referenced above.
The major countries covered in the heparin market report are the China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China is dominating the market due to the increasing geriatric population, large population with chronic disease, and growing economies. The region is also the largest supplier of crude heparin and its API. This gives an added benefit to local firms, such as Pharmax Lifesciences. Local companies are producing cost-effective generic medicines of patent-expired drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Heparin Market Share Analysis
The heparin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to heparin market.
Key players operating in the heparin market include:
- Sanofi (France)
- Pfizer Inc (U.S.)
- Merck & Co., Inc. (U.S.)
- Abbott (U.S.)
- Mylan N.V. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Aspen Holdings (U.S.)
- Changzhaou Qianhong Bio-pharma Co., ltd. (China)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
- Hikma Pharmaceuticals PLC (U.K.)
- Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
- OPOCRIN SPA (Italy)
- SARIA International GmbH (Germany)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
- Hepalink Group. (China)
SKU-